



Australian Technical Advisory Group on Immunisation (ATAGI)

Summary of the 124th meeting, 26 August 2026

COVID-19

- From 1 October 2026, COVID-19 vaccines will transition to the National Immunisation Program (NIP). Eligibility for funded COVID-19 vaccines will continue to focus on people at highest risk of severe disease. The department has published an [update on COVID-19 vaccines for immunisation providers](#), and further communications for providers and consumers will be published during September 2026.
- ATAGI reviewed a draft clinical statement on the transition of COVID-19 vaccines to the NIP, which will be published in September. The [COVID-19 chapter of the Australian Immunisation Handbook](#) will be updated on 1 October 2026.

Pneumococcal disease

- ATAGI reviewed and discussed a GRADE assessment on the use of 21-valent pneumococcal vaccine in children and adolescents with risk conditions.

Dengue

- ATAGI reviewed and discussed a draft clinical statement on the use of [Qdenga dengue vaccine](#). When published, this statement will give interim guidance for immunisation providers until a new dengue chapter of the Handbook is developed.

ATAGI publications

- ATAGI reviewed and discussed updates to the Australian Immunisation Handbook chapter on [rabies and other lyssaviruses](#). ATAGI will work with the Communicable Diseases Network Australia to align the Handbook chapter and the [Series of National Guidelines for public health units](#).

Departmental updates

- ATAGI received an update from the department on a strategic project to review the value and performance of the NIP.
- ATAGI reviewed analysis from the department on predicted versus actual uptake of RSV (respiratory syncytial virus) vaccines.

Other ATAGI business

- ATAGI reviewed and discussed its advice to the Pharmaceutical Benefits Advisory Committee (PBAC) for upcoming immunisation products.

Resources

- ATAGI's membership, terms of reference and declaration of interest information is available on the [Department of Health, Disability and Ageing website](#).